Cervix CancerNCT03239626
Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer
A study testing POHIM-RT in people with Cervix Cancer and Radiotherapy, Adjuvant, run by Samsung Medical Center at 1 site in South Korea.
Trial summary
To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy. Read more about this study
- Who is it for?
- Ages 20 to 70 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cervix Cancer, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated
- What is being tested?
- POHIM-RT
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteSouth Korea
- Study dates
- 31 Aug 2017to 28 Apr 2025
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- histologically confirmed cervical cancer
- radical hysterectomy and pelvic lymph node dissection was done
- histologically indicated adjuvant radiotherapy ( more than one as below)
- tumor size ≥4 cm
- positive lymphovascular invasion
- more than half stromal invasion depth
- ECOG performance status 0 or 1
- Bone marrow function: granulocyte ≥1.0 x 1000/µl, platelet ≥30 x 1000/µl, hemoglobin ≥10 g/dl
Who cannot join
- positive pelvic lymph node metastasis
- positive distant metastasis (including retroperitoneal lymph node metastasis)
- positive tumor involvement on resection margin
- positive parametrial invasion
- previous history of pelvic radiotherapy
- more than 3 months after radical surgery for cervical cancer
- neoadjuvant chemotherapy was done
- previous history of other carcinoma except for thyroid cancer, skin cancer, in situ carcinoma on cervix
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer: a Prospective Exploratory Trial (POHIM_RT Trial)
To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.
- Conditions
- Cervix Cancer, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated, Hypofractionated Dose
- Being tested
- POHIM-RT
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
POHIM-RTRadiation
postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
| Study group | Role | What they receive |
|---|---|---|
| POHIM-RT | Experimental | adjuvant hypofractionated IMRT for cervical cancer patients Receives: Radiation: POHIM-RT |
What is being measured
The primary outcome is the main question the study is designed to answer.
acute toxicities according to CTCAE v4.0
evaluation of acute toxicities within 3months after radiotherapy according to CTCAE v4.0
Measured: 3 months
Secondary outcomes (2)
late toxicities according to CTCAE v4.0
evaluation of late toxicities every year after 3months after radiotherapy according to CTCAE v4.0
Measured: 5-years
Progression free survival rate
progression free survival rate after the time of surgery
Measured: 5-years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2017
- Study start31 Aug 2017
- Primary completion28 Apr 2025 (estimated)
- Study completion28 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cervix CancerStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- One group for hypofractionaed IMRT for adjvuant cervical cancer patients
- Masking
- None (open label)
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Won Park, M.D.,Ph.D, Principal investigator, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03239626
- Sponsor's protocol ID
- SMC 2017-03-092-002
- Status last verified
- Nov 2024
- First submitted
- 2 Aug 2017
- Last updated
- 3 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cho WK, Park W, Kim SW, Lee KK, Ahn KJ, Yoon M, Choi JH. Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study). Gynecol Oncol. 2025 Jul;198:84-89. doi: 10.1016/j.ygyno.2025.05.020. Epub 2025 May 30.
PubMed 40449127